- Y Diweddaraf sydd Ar Gael (Diwygiedig)
- Pwynt Penodol mewn Amser (12/02/2007)
- Gwreiddiol (Fel y’i mabwysiadwyd gan yr UE)
Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (repealed)
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
Mae unrhyw newidiadau sydd wedi cael eu gwneud yn barod gan y tîm yn ymddangos yn y cynnwys a chyfeirir atynt gydag anodiadau.Ar ôl y diwrnod ymadael bydd tair fersiwn o’r ddeddfwriaeth yma i’w gwirio at ddibenion gwahanol. Y fersiwn legislation.gov.uk yw’r fersiwn sy’n weithredol yn y Deyrnas Unedig. Y Fersiwn UE sydd ar EUR-lex ar hyn o bryd yw’r fersiwn sy’n weithredol yn yr UE h.y. efallai y bydd arnoch angen y fersiwn hon os byddwch yn gweithredu busnes yn yr UE. EUR-Lex Y fersiwn yn yr archif ar y we yw’r fersiwn swyddogol o’r ddeddfwriaeth fel yr oedd ar y diwrnod ymadael cyn cael ei chyhoeddi ar legislation.gov.uk ac unrhyw newidiadau ac effeithiau a weithredwyd yn y Deyrnas Unedig wedyn. Mae’r archif ar y we hefyd yn cynnwys cyfraith achos a ffurfiau mewn ieithoedd eraill o EUR-Lex. The EU Exit Web Archive legislation_originated_from_EU_p3
Version Superseded: 21/08/2007
Point in time view as at 12/02/2007.
There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I .
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
Textual Amendments
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
All substances belonging to the sulfonamide group | Parent drug | All food-producing species | 100 μg/kg | Muscle | The combined total residues of all substances within the sulfonamide group should not exceed 100 μg/kg |
100 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
100 μg/kg | Kidney | ||||
Bovine, ovine, caprine | 100 μg/kg | Milk |
a [F2For porcine and poultry species this MRL relates to ‘ skin and fat in natural proportions ’ . | |||||
b For fin fish this MRL relates to ‘ muscle and skin in natural proportions ’ .] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Baquiloprim | Baquiloprim | Bovine | 10 μg/kg | Fat | |
300 μg/kg | Liver | ||||
150 μg/kg | Kidney | ||||
30 μg/kg | Milk | ||||
Porcine | 40 μg/kg | Skin and fat | |||
50 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
[F3Trimethoprim | Trimethoprim | All food producing species except equidae | 50 μg/kg | Fat a | Not for use in animals from which eggs are produced for human consumption |
50 μg/kg | Muscle b | ||||
50 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
50 μg/kg | Milk | ||||
Equidae | 100 μg/kg | Muscle | |||
100 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
100 μg/kg | Kidney] |
Textual Amendments
F2 Inserted by Commission Regulation (EC) No 1181/2002 of 1 July 2002 amending Annex I of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F3 Substituted by Commission Regulation (EC) No 1181/2002 of 1 July 2002 amending Annex I of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
a [F4For intramammary use only. | |||||
b [F5Not for use in animals from which eggs are produced for human consumption.] ] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Amoxicyllin | Amoxicyllin | All food-producing species | 50 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
50 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
4 μg/kg | Milk | ||||
Ampicillin | Ampicillin | All food-producing species | 50 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
50 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
4 μg/kg | Milk | ||||
Benzylpenicillin | Benzylpenicillin | All food-producing species | 50 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
50 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
4 μg/kg | Milk | ||||
Cloxacillin | Cloxacillin | All food-producing species | 300 μg/kg | Muscle | |
300 μg/kg | Fat | ||||
300 μg/kg | Liver | ||||
300 μg/kg | Kidney | ||||
30 μg/kg | Milk | ||||
Dicloxacillin | Dicloxacillin | All food-producing species | 300 μg/kg | Muscle | |
300 μg/kg | Fat | ||||
300 μg/kg | Liver | ||||
300 μg/kg | Kidney | ||||
30 μg/kg | Milk | ||||
[F6Nafcillin | Nafcillin | All ruminants a | 300 μg/kg | Muscle | |
300 μg/kg | Fat | ||||
300 μg/kg | Liver | ||||
300 μg/kg | Kidney | ||||
30 μg/kg | Milk] | ||||
Oxacillin | Oxacillin | All food-producing species | 300 μg/kg | Muscle | |
300 μg/kg | Fat | ||||
300 μg/kg | Liver | ||||
300 μg/kg | Kidney | ||||
30 μg/kg | Milk | ||||
Penethamate | Benzylpenicillin | Bovine | 50 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
50 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
4 μg/kg | Milk | ||||
[F7 | Porcine | 50 μg/kg | Muscle | ||
50 μg/kg | Fat | ||||
50 μg/kg | Liver | ||||
50 μg/kg | Kidney | ] | |||
[F8 | All mammalian-food producing species | 50 μg/kg | Muscle | ||
50 μg/kg | Fat | ||||
50 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
4 μg/kg | Milk | ] | |||
[F9Phenoxymethylpenicillin | Phenoxymethylpenicillin | Porcine | 25 μg/kg | Muscle | |
25 μg/kg | Liver | ||||
25 μg/kg | Kidney | ||||
[F5Poultry b | 25 μg/kg | Muscle | |||
25 μg/kg | Skin + fat | ||||
25 μg/kg | Liver | ||||
25 μg/kg | Kidney | ] ] |
Textual Amendments
F4 Inserted by Commission Regulation (EC) No 546/2004 of 24 March 2004 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F5 Inserted by Commission Regulation (EC) No 1299/2005 of 8 August 2005 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards phenoxymethylpenicillin, phoxim, norgestomet and thiamphenicol (Text with EEA relevance).
F6 Substituted by Commission Regulation (EC) No 546/2004 of 24 March 2004 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F7 Inserted by Commission Regulation (EC) No 2757/1999 of 22 December 1999 amending Annexes I and II of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F8 Inserted by Commission Regulation (EC) No 1148/2005 of 15 July 2005 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards penethamate (Text with EEA relevance).
F9 Inserted by Commission Regulation (EC) No 1286/2000 of 19 June 2000 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
a [F10For porcine species this MRL relates to ‘ skin and fat in natural proportions ’ .] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F11Cefacetrile | Cefacetrile | Bovine | 125 μg/kg | Milk | For intramammary use only] |
[F12Cefalexin | Cefalexin | Bovine | 200 μg/kg | Muscle | |
200 μg/kg | Fat | ||||
200 μg/kg | Liver | ||||
1 000 μg/kg | Kidney | ||||
100 μg/kg | Milk | ] | |||
[F13Cefalonium | Cefalonium | Bovine | 20 μg/kg | Milk | ] |
[F14Cefapirin | Sum of cephapirin and desacetylcephapirin | Bovine | 50 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
100 μg/kg | Kidney | ||||
60 μg/kg | Milk | ] | |||
Cefazolin | Cefazolin | Bovine, ovine, caprine | 50 μg/kg | Milk | |
[F15Cefoperazone | Cefoperazone | Bovine | 50 μg/kg | Milk | ] |
Cefquinome | Cefquinome | Bovine | 50 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
20 μg/kg | Milk | ||||
[F16 | Porcine | 50 μg/kg | Muscle | ||
50 μg/kg | Skin + fat | ||||
100 μg/kg | Liver | ||||
200 μg/kg | Kidney | ] | |||
[F17 | Equidae | 50 μg/kg | Muscle | ||
50 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
200 μg/kg | Kidney | ] | |||
[F18Ceftiofur | Sum of all residues retaining the betalactam structure expressed as desfuroylceftiofur | All mammalian food-producing species | 1 000 μg/kg | Muscle | |
2 000 μg/kg | Fat a | ||||
2 000 μg/kg | Liver | ||||
6 000 μg/kg | Kidney | ||||
100 μg/kg | Milk] |
Textual Amendments
F10 Inserted by Commission Regulation (EC) No 1231/2006 of 16 August 2006 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards ceftiofur and polyoxyethylene sorbitan monooleate and trioleate (Text with EEA relevance).
F11 Inserted by Commission Regulation (EC) No 2162/2001 of 7 November 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F12 Inserted by Commission Regulation (EC) No 2728/1999 of 20 December 1999 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F13 Inserted by Commission Regulation (EC) No 61/2003 of 15 January 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F14 Inserted by Commission Regulation (EC) No 1553/2001 of 30 July 2001 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F15 Inserted by Commission Regulation (EC) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F16 Inserted by Commission Regulation (EC) No 1931/1999 of 9 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F17 Inserted by Commission Regulation (EC) No 2145/2003 of 8 December 2003 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F18 Substituted by Commission Regulation (EC) No 1231/2006 of 16 August 2006 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards ceftiofur and polyoxyethylene sorbitan monooleate and trioleate (Text with EEA relevance).
a [F2For fin fish this MRL relates to ‘ muscle and skin in natural proportions ’ . | |||||
b For porcine species this MRL relates to ‘ skin and fat in natural proportions ’ . | |||||
c [F19Not for use in animals from which milk or eggs are produced for human consumption; MRLs for fat, liver and kidney do not apply to fin fish. | |||||
d For porcine and poultry species this MRL relates to ‘ skin and fat in natural proportions ’ .] ] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F3Danofloxacin | Danofloxacin | [X1All food producing species except bovine, ovine, caprine, porcine and poultry] | 100 μg/kg | Muscle b | |
50 μg/kg | Fat a | ||||
200 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
Bovine, ovine, caprine | 200 μg/kg | Muscle | |||
100 μg/kg | Fat | ||||
400 μg/kg | Liver | ||||
400 μg/kg | Kidney | ||||
30 μg/kg | Milk | ||||
Poultry | 200 μg/kg | Muscle | Not for use in animals from which eggs are produced for human consumption | ||
100 μg/kg | Skin and fat | ||||
400 μg/kg | Liver | ||||
400 μg/kg | Kidney | ||||
Difloxacin | Difloxacin | All food producing species except bovine, ovine, caprine and poultry | 300 μg/kg | Muscle b | |
100 μg/kg | Fat | ||||
800 μg/kg | Liver | ||||
600 μg/kg | Kidney | ||||
Bovine, ovine, caprine | 400 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption | ||
100 μg/kg | Fat | ||||
1 400 μg/kg | Liver | ||||
800 μg/kg | Kidney | ||||
Porcine | 400 μg/kg | Muscle | |||
100 μg/kg | Skin and fat | ||||
800 μg/kg | Liver | ||||
800 μg/kg | Kidney | ||||
Poultry | 300 μg/kg | Muscle | Not for use in animals from which eggs are produced for human consumption | ||
400 μg/kg | Skin and fat | ||||
1 900 μg/kg | Liver | ||||
600 μg/kg | Kidney | ||||
Enrofloxacin | Sum of enrofloxacin and ciprofloxacin | All food producing species except bovine, ovine, caprine, porcine, rabbits and poultry | 100 μg/kg | Muscle b | |
100 μg/kg | Fat | ||||
200 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
Bovine, ovine, caprine | 100 μg/kg | Muscle | |||
100 μg/kg | Fat | ||||
300 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
100 μg/kg | Milk | ||||
Porcine, rabbits | 100 μg/kg | Muscle | |||
100 μg/kg | Fat a | ||||
200 μg/kg | Liver | ||||
300 μg/kg | Kidney | ||||
Poultry | 100 μg/kg | Muscle | Not for use in animals from which eggs are produced for human consumption | ||
100 μg/kg | Skin and fat | ||||
200 μg/kg | Liver | ||||
300 μg/kg | Kidney | ||||
Flumequine | Flumequine | All food producing species except bovine, ovine, caprine, porcine, poultry and fin fish | 200 μg/kg | Muscle | |
250 μg/kg | Fat | ||||
500 μg/kg | Liver | ||||
1 000 μg/kg | Kidney | ||||
Bovine, porcine, ovine, caprine | 200 μg/kg | Muscle | |||
300 μg/kg | Fat a | ||||
500 μg/kg | Liver | ||||
1 500 μg/kg | Kidney | ||||
50 μg/kg | Milk | ||||
Poultry | 400 μg/kg | Muscle | Not for use in animals from which eggs are produced for human consumption | ||
250 μg/kg | Skin and fat | ||||
800 μg/kg | Liver | ||||
1 000 μg/kg | Kidney | ||||
Fin fish | 600 μg/kg | Muscle and skin in natural proportion | ] | ||
[F20Marbofloxacin | Marbofloxacin | Bovine | 150 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
150 μg/kg | Liver | ||||
150 μg/kg | Kidney | ||||
75 μg/kg | Milk | ||||
Porcine | 150 μg/kg | Muscle | |||
50 μg/kg | Skin and fat | ||||
150 μg/kg | Liver | ||||
150 μg/kg | Kidney | ] | |||
[F21Oxolinic acid | Oxolinic acid | Porcine | 100 μg/kg | Muscle | |
50 μg/kg | Skin and fat | ||||
150 μg/kg | Liver | ||||
150 μg/kg | Kidney | ||||
Chicken | 100 μg/kg | Muscle | Not for use in animals from which eggs are produced for human consumption | ||
50 μg/kg | Skin and fat | ||||
150 μg/kg | Liver | ||||
150 μg/kg | Kidney | ||||
Fin fish | 100 μg/kg | Muscle and skin in natural proportions | |||
[F19All food-producing species c | 100 μg/kg | Muscle a | |||
50 μg/kg | Fat d | ||||
150 μg/kg | Liver | ||||
150 μg/kg | Kidney | ] ] | |||
Sarafloxacin | Sarafloxacin | Chicken | 10 μg/kg | Skin and fat | |
100 μg/kg | Liver | ||||
Salmonidae | 30 μg/kg | Muscle and skin in natural proportions |
Editorial Information
X1 Substituted by Corrigendum to Commission Regulation (EC) No 1181/2002 of 1 July 2002 amending Annex I of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Official Journal of the European Communities L 172 of 2 July 2002).
Textual Amendments
F19 Inserted by Commission Regulation (EC) No 1356/2005 of 18 August 2005 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards oxolinic acid and morantel (Text with EEA relevance).
F20 Inserted by Commission Regulation (EC) No 2338/2000 of 20 October 2000 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F21 Inserted by Commission Regulation (EC) No 739/2003 of 28 April 2003 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
a [F2For fin fish this MRL relates to a ‘ muscle and skin in natural proportions ’ . | |||||
b For procine species this MRL relates to ‘ skin and fat in natural proportions ’ . | |||||
c For porcine and poultry species this MRL relates to ‘ skin and fat in natural proportions ’ . | |||||
e [F23Not for use in animals from which milk is produced for human consumption.] ] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F24Acetylisovaleryltylosin | Sum of acetyl-isovaleryltylosin and 3-O-acetyltylosin | Porcine | 50 μg/kg | Muscle | |
50 μg/kg | Skin and fat | ||||
50 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
[F23Poultry e | 50 μg/kg | Skin + fat | |||
50 μg/kg | Liver | ] ] | |||
[F3Erythromycin | Erythromicyin A | All food producing species | 200 μg/kg | Muscle a | |
200 μg/kg | Fat b | ||||
200 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
40 μg/kg | Milk | ||||
150 μg/kg | Eggs | ] | |||
Spiramycin | Sum of spiramycin and neospiramycin | Bovine | 200 μg/kg | Muscle | |
300 μg/kg | Fat | ||||
300 μg/kg | Liver | ||||
300 μg/kg | Kidney | ||||
200 μg/kg | Milk | ||||
Chicken | 200 μg/kg | Muscle | |||
300 μg/kg | Skin and fat | ||||
400 μg/kg | Liver | ||||
[F25 | Spiramycin 1 | Porcine | 250 μg/kg | Muscle | |
2 000 μg/kg | Liver | ||||
1 000 μg/kg | Kidney | ] | |||
[F3Tilmicosin | Tilmicosin | All food producing species except poultry | 50 μg/kg | Muscle a | |
50 μg/kg | Fat b | ||||
1 000 μg/kg | Liver | ||||
1 000 μg/kg | Kidney | ||||
50 μg/kg | Milk | ||||
Poultry | 75 μg/kg | Muscle | Not for use in animals from which eggs are produced for human consumption | ||
75 μg/kg | Sin and fat | ||||
1 000 μg/kg | Liver | ||||
250 μg/kg | Kidney | ||||
[F22 [X2Tulathromycin | (2R,3S,4R,5R,8R,10R,11R,12S, 13S,14R)-2-ethyl-3,4,10,13-tetrahydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-ß-D-xylo-hexopy-ranosyl]oxy]-1-oxa-6-azacyclopent-decan-15-one expressed as tulathromycin equivalents | Bovine d | 100 μg/kg | Fat | |
3 000 μg/kg | Liver | ||||
3 000 μg/kg | Kidney | ||||
Porcine | 100 μg/kg | Skin + fat | |||
3 000 μg/kg | Liver | ||||
3 000 μg/kg | Kidney | ] ] | |||
Tylosin | Tylosin A | All food producing species | 100 μg/kg | Fat c | |
100 μg/kg | Muscle a | ||||
100 μg/kg | Liver | ||||
100 μg/kg | Kidney | ||||
50 μg/kg | Milk | ||||
200 μg/kg | Eggs | ] |
Editorial Information
X2 Substituted by Corrigendum to Commission Regulation (EC) No 1101/2004 of 10 June 2004 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Official Journal of the European Union L 211 of 12 June 2004).
Textual Amendments
F22 Inserted by Commission Regulation (EC) No 1101/2004 of 10 June 2004 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F23 Inserted by Commission Regulation (EC) No 1518/2005 of 19 September 2005 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards acetylisovaleryltylosin and fluazuron (Text with EEA relevance).
F24 Inserted by Commission Regulation (EC) No 77/2002 of 17 January 2002 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F25 Inserted by Commission Regulation (EC) No 2593/1999 of 8 December 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
a Not for use in animals from which eggs are produced for human consumption, MRLs for fat, liver and kidney do not apply to fin fish. | ||||
b For fin fish muscle relates to ‘ muscle and skin in natural proportions ’ . | ||||
c For porcine and poultry species this MRL relates to ‘ skin and fat in natural proportions ’ .] | ||||
Pharmacologically active Substance(s) | Marker residue | Animal species | MRLs | Target tissues |
---|---|---|---|---|
Thiamphenicol | Thiamphenicol | All food producing species a | 50 μg/kg | Muscle b |
50 μg/kg | Fat c | |||
50 μg/kg | Liver | |||
50 μg/kg | Kidney | |||
50 μg/kg | Milk |
Textual Amendments
F26 Substituted by Commission Regulation (EC) No 1805/2006 of 7 December 2006 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards thiamphenicol, fenvalerate and meloxicam (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Chlortetracycline | Sum of parent drug and its 4- epimer | All food-producing species | 100 μg/kg | Muscle | |
300 μg/kg | Liver | ||||
600 μg/kg | Kidney | ||||
100 μg/kg | Milk | ||||
200 μg/kg | Eggs | ||||
Doxycycline | Doxycycline | Bovine | 100 μg/kg | Muscle | |
Not for use in animals from which milk is produced for human consumption | 300 μg/kg | Liver | |||
600 μg/kg | Kidney | ||||
Porcine | 100 μg/kg | Muscle | |||
300 μg/kg | Skin and fat | ||||
300 μg/kg | Liver | ||||
600 μg/kg | Kidney | ||||
Poultry | 100 μg/kg | Muscle | |||
Not for use in animals from which eggs are produced for human consumption | 300 μg/kg | Skin and fat | |||
300 μg/kg | Liver | ||||
600 μg/kg | Kidney | ||||
Oxytetracycline | Sum of parent drug and its 4-epimer | All food-producing species | 100 μg/kg | Muscle | |
300 μg/kg | Liver | ||||
600 μg/kg | Kidney | ||||
100 μg/kg | Milk | ||||
200 μg/kg | Eggs | ||||
Tetracycline | Sum of parent drug and its 4-epimer | All food-producing species | 100 μg/kg | Muscle | |
300 μg/kg | Liver | ||||
600 μg/kg | Kidney | ||||
100 μg/kg | Milk | ||||
200 μg/kg | Eggs |
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Rifaximin | Rifaximin | Bovine | 60 μg/kg | Milk |
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F12Tiamulin | Sum of metabolites that may be hydrolysed to 8-a-hydroxymutilin | Porcine | 100 μg/kg | Muscle | |
500 μg/kg | Liver | ||||
Chicken | 100 μg/kg | Muscle | |||
100 μg/kg | Skin and fat | ||||
1 000 μg/kg | Liver | ||||
[F20Rabbits | 100 μg/kg | Muscle | |||
500 μg/kg | Liver | ] | |||
[F15Turkey | 100 μg/kg | Muscle | |||
100 μg/kg | Skin and fat | ||||
300 μg/kg | Liver | ] | |||
Tiamulin | 1 000 μg/kg | Eggs | ] | ||
Valnemulin | Valnemulin | Porcine | 50 μg/kg | Muscle | |
500 μg/kg | Liver | ||||
100 μg/kg | Kidney |
a [F2For porcine and poultry species this MRL relates to ‘ skin and fat in natural proportions ’ . | |||||
b For fin fish this MRL relates to ‘ muscle and skin in natural proportions ’ .] ] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F3Lincomycin | Lincomicyn | All food producing species | 50 μg/kg | Fat a | |
100 μg/kg | Muscle b | ||||
500 μg/kg | Liver | ||||
1 500 μg/kg | Kidney | ||||
150 μg/kg | Milk | ||||
50 μg/kg | Eggs | ] | |||
[F20Pirlimycin | Pirlimycin | Bovine | 100 μg/kg | Muscle | |
100 μg/kg | Fat | ||||
1 000 μg/kg | Liver | ||||
400 μg/kg | Kidney | ||||
100 μg/kg | Milk | ||||
Porcine | 100 μg/kg | Muscle | |||
50 μg/kg | Skin and fat | ||||
500 μg/kg | Liver | ||||
1 500 μg/kg | Kidney | ||||
Chicken | 100 μg/kg | Muscle | |||
50 μg/kg | Skin and fat | ||||
500 μg/kg | Liver | ||||
1 500 μg/kg | Kidney | ||||
50 μg/kg | Eggs | ] |
Textual Amendments
F27 Inserted by Commission Regulation (EC) No 804/1999 of 16 April 1999 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
a [F2For porcine and poultry species this MRL relates to ‘ skin and fat in natural proportions ’ . | |||||
b For fin fish this MRL relates to ‘ muscle and skin in natural proportions ’ . | |||||
c [F28Not for use in animals from which eggs are produced for human consumption.] ] ] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Apramycin | Apramycin | Bovine | 1 000 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
1 000 μg/kg | Fat | ||||
10 000 μg/kg | Liver | ||||
20 000 μg/kg | Kidney | ||||
[F29Dihydrostreptomycin | Dihydrostreptomycin | Bovine, ovine | 500 μg/kg | Muscle | |
500 μg/kg | Fat | ||||
500 μg/kg | Liver | ||||
1 000 μg/kg | Kidney | ||||
200 μg/kg | Milk | ||||
Porcine | 500 μg/kg | Muscle | |||
500 μg/kg | Skin and fat | ||||
500 μg/kg | Liver | ||||
1 000 μg/kg | Kidney | ||||
[F30All ruminants | 500 μg/kg | Muscle | |||
500 μg/kg | Fat | ||||
500 μg/kg | Liver | ||||
1 000 μg/kg | Kidney | ||||
200 μg/kg | Milk | ] ] | |||
[F31Gentamicin | Sum of gentamicin C1, gentamicin C1a, gentamicin C2 and gentamicin C2a | Bovine | 50 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
200 μg/kg | Liver | ||||
750 μg/kg | Kidney | ||||
100 μg/kg | Milk | ||||
Porcine | 50 μg/kg | Muscle | |||
50 μg/kg | Skin and fat | ||||
200 μg/kg | Liver | ||||
750 μg/kg | Kidney | ] | |||
[F28Kanamycin | Kanamycin A | All food producing species except fish c | 100 μg/kg | Muscle | |
100 μg/kg | Fat a | ||||
600 μg/kg | Liver | ||||
2 500 μg/kg | Kidney | ||||
150 μg/kg | Milk | ] | |||
[F2Neomycin (including framycetin) | Neomycin B | All food producing species | 500 μg/kg | Fat a | |
500 μg/kg | Muscle b | ||||
500 μg/kg | Liver | ||||
5 000 μg/kg | Kidney | ||||
1 500 μg/kg | Milk | ||||
500 μg/kg | Eggs | ] | |||
[F3Paromomycin | Paromomycin | All food producing species | 500 μg/kg | Muscle b | Not for use in animals from which milk or eggs are produced for human consumption |
1 500 μg/kg | Liver | ||||
1 500 μg/kg | Kidney | ||||
Spectinomycin | Spectinomycin | All food producing species except ovine | 500 μg/kg | Fat a | Not for use in animals from which eggs are produced for human consumption |
300 μg/kg | Muscle b | ||||
1 000 μg/kg | Liver | ||||
5 000 μg/kg | Kidney | ||||
200 μg/kg | Milk | ||||
Ovine | 300 μg/kg | Muscle | |||
500 μg/kg | Fat | ||||
2 000 μg/kg | Liver | ||||
5 000 μg/kg | Kidney | ||||
200 μg/kg | Milk] | ||||
[F29Streptomycin | Streptomycin | Bovine, ovine | 500 μg/kg | Muscle | |
500 μg/kg | Fat | ||||
500 μg/kg | Liver | ||||
1 000 μg/kg | Kidney | ||||
200 μg/kg | Milk | ||||
Porcine | 500 μg/kg | Muscle | |||
500 μg/kg | Skin and fat | ||||
500 μg/kg | Liver | ||||
1 000 μg/kg | Kidney | ] |
Textual Amendments
F28 Inserted by Commission Regulation (EC) No 324/2004 of 25 February 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F29 Inserted by Commission Regulation (EC) No 1530/2002 of 27 August 2002 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F30 Inserted by Commission Regulation (EC) No 6/2006 of 5 January 2006 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards dihydrostreptomycin, tosylchloramide sodium and Piceae turiones recentes extractum (Text with EEA relevance).
F31 Inserted by Commission Regulation (EC) No 868/2002 of 24 May 2002 amending Annexes I and II of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Novobiocin | Novobiocin | Bovine | 50 μg/kg | Milk | ] |
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Bacitracin | Sum of bacitracin A, bacitracin B, and bacitracin C | Bovine | 100 μg/kg | Milk | |
[F33 | Rabbits | 150 μg/kg | Muscle | ||
150 μg/kg | Fat | ||||
150 μg/kg | Liver | ||||
150 μg/kg | Kidney | ] ] |
Textual Amendments
F33 Inserted by Commission Regulation (EC) No 544/2003 of 27 March 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Textual Amendments
F32 Inserted by Commission Regulation (EC) No 1478/2001 of 18 July 2001 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Clavulanic acid | Clavulanic acid | Bovine | 100 μg/kg | Muscle | |
100 μg/kg | Fat | ||||
200 μg/kg | Liver | ||||
400 μg/kg | Kidney | ||||
200 μg/kg | Milk | ||||
Porcine | 100 μg/kg | Muscle | |||
100 μg/kg | Skin and fat | ||||
200 μg/kg | Liver | ||||
400 μg/kg | Kidney | ] |
a For porcine and poultry species this MRL relates to ‘ skin and fat in natural proportions ’ . | |||||
b For fin fish this MRL relates to ‘ muscle and skin in natural proportions ’ .] | |||||
Pharmacologically active substance | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Colistin | Colistin | All food producing species | 150 μg/kg | Fat a | |
150 μg/kg | Muscle b | ||||
150 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
50 μg/kg | Milk | ||||
300 μg/kg | Eggs |
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Closantel | Closantel | Bovine | 1 000 μg/kg | Muscle | |
3 000 μg/kg | Fat | ||||
1 000 μg/kg | Liver | ||||
3 000 μg/kg | Kidney | ||||
Ovine | 1 500 μg/kg | Muscle | |||
2 000 μg/kg | Fat | ||||
1 500 μg/kg | Liver | ||||
5 000 μg/kg | Kidney | ||||
[F32Rafoxanide | Rafoxanide | Bovine | 30 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
30 μg/kg | Fat | ||||
10 μg/kg | Liver | ||||
40 μg/kg | Kidney | ||||
Ovine | 100 μg/kg | Muscle | |||
250 μg/kg | Fat | ||||
150 μg/kg | Liver | ||||
150 μg/kg | Kidney] |
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Levamisole | Levamisole | Bovine, ovine, porcine, poultry | 10 μg/kg | Muscle | |
10 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
10 μg/kg | Kidney |
a [F34Not for use in animals producing milk for human consumption.] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F35Albendazole | Sum of albendazole sulphoxide, albendazole sulphone, and albendazole 2-amino sulphone, expressed as albendazole | All ruminants | 100 μg/kg | Muscle | |
100 μg/kg | Fat | ||||
1 000 μg/kg | Liver | ||||
500 μg/kg | Kidney | ||||
100 μg/kg | Milk] | ||||
[F36Albendazole oxide | Sum of albendazole oxide, albendazole sulphone and albendazole 2-aminosulphone, expressed as albendazole | Bovine, ovine | 100 μg/kg | Muscle | |
100 μg/kg | Fat | ||||
1 000 μg/kg | Liver | ||||
500 μg/kg | Kidney | ||||
100 μg/kg | Milk | ] | |||
[F35Febantel | Sum of extractable residues which may be oxidised to oxfendazole sulphone | All ruminants | 50 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
500 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
10 μg/kg | Milk | ||||
Fenbendazole | Sum of extractable residues which may be oxidised to oxfendazole sulphone | All ruminants | 50 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
500 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
10 μg/kg | Milk] | ||||
[F37Flubendazole | Sum of flubendazole and (2-amino 1H-benzimidazol-5-yl) (4fluorophenyl) methanone | Poultry, porcine | 50 μg/kg | Muscle | |
50 μg/kg | Skin + fat | ||||
400 μg/kg | Liver | ||||
300 μg/kg | Kidney | ||||
Flubendazole | Flubendazole | Poultry | 400 μg/kg | Eggs | ] |
[F38Mebendazole | Sum of mebendazole methyl (5-(1-hydroxy, 1-phenyl) methyl-1H-benzimidazol-2-yl) carbamate and (2-amino-1H-benzimidazol-5-yl) phenylmethanone, expressed as mebendazole equivalents | Ovine, caprine, equidae | 60 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
60 μg/kg | Fat | ||||
400 μg/kg | Liver | ||||
60 μg/kg | Kidney] | ||||
[F15Netobimin | Sum of albendazole oxide, albendazole sulphone and albendazole 2-aminosulphone, expressed as albendazole | [X3Bovine, ovine] | 100 μg/kg | Muscle | For oral use only |
100 μg/kg | Fat | ||||
1 000 μg/kg | Liver | ||||
500 μg/kg | Kidney | ||||
100 μg/kg | Milk] | ||||
[F35Oxfendazole | Sum of extractable residues which may be oxidised to oxfendazole sulphone | All ruminants | 50 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
500 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
10 μg/kg | Milk] | ||||
Oxibendazole | Oxibendazole | Porcine | 100 μg/kg | Muscle | |
500 μg/kg | Skin and fat | ||||
200 μg/kg | Liver | ||||
100 μg/kg | Kidney | ||||
[F35Thiabendazole | Sum of thiabendazole and 5-hydroxythiabendazole | Caprine | 100 μg/kg | Muscle | |
100 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
100 μg/kg | Kidney | ||||
100 μg/kg | Milk] | ||||
[F39Triclabendazole | Sum of extractable residues that may be oxidised to ketotriclabendazole | All ruminants a | 225 μg/kg | Muscle | |
100 μg/kg | Fat | ||||
250 μg/kg | Liver | ||||
150 μg/kg | Kidney] |
Editorial Information
X3 Substituted by Corrigendum to Commission Regulation (EC) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Official Journal of the European Communities L 118 of 27 April 2001).
Textual Amendments
F34 Inserted by Commission Regulation (EC) No 1729/2006 of 23 November 2006 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards firocoxib and triclabendazole (Text with EEA relevance).
F35 Substituted by Commission Regulation (EC) No 1646/2004 of 20 September 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F36 Inserted by Commission Regulation (EC) No 2393/1999 of 11 November 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F37 Substituted by Commission Regulation (EC) No 1055/2006 of 12 July 2006 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards flubendazole and lasalocid (Text with EEA relevance).
F38 Inserted by Commission Regulation (EC) No 1680/2001 of 22 August 2001 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F39 Substituted by Commission Regulation (EC) No 1729/2006 of 23 November 2006 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards firocoxib and triclabendazole (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Nitroxinil | Nitroxinil | Bovine, ovine | 400 μg/kg | Muscle | |
200 μg/kg | Fat | ||||
20 μg/kg | Liver | ||||
400 μg/kg | Kidney | ||||
[F35Oxyclozanide | Oxyclozanide | All ruminants | 20 μg/kg | Muscle | |
20 μg/kg | Fat | ||||
500 μg/kg | Liver | ||||
100 μg/kg | Kidney | ||||
10 μg/kg | Milk] ] |
Textual Amendments
F40 Inserted by Commission Regulation (EC) No 997/1999 of 11 May 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Clorsulon | Clorsulon | Bovine | 35 μg/kg | Muscle | |
100 μg/kg | Liver | ||||
200 μg/kg | Kidney | ] |
Textual Amendments
F41 Inserted by Commission Regulation (EC) No 1942/1999 of 10 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Piperazine | Piperazine | Porcine | 400 μg/kg | Muscle | |
800 μg/kg | Skind and fat | ||||
2 000 μg/kg | Liver | ||||
1 000 μg/kg | Kidney | ||||
Chicken | 2 000 μg/kg | Eggs | ] |
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Morantel | Sum of residues which may be hydrolysed to N-methyl-1,3- propanediamine and expressed as morantel equivalents | Bovine, ovine | 100 μg/kg | Muscle | |
100 μg/kg | Fat | ||||
800 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
50 μg/kg | Milk | ||||
[F19All ruminants | 100 μg/kg | Muscle | |||
100 μg/kg | Fat | ||||
800 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
50 μg/kg | Milk | ] ] |
Textual Amendments
F42 Inserted by Commission Regulation (EC) No 1851/2004 of25 October 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits for veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F32Coumafos | Coumafos | Bees | 100 μg/kg | Honey | ] |
Diazinon | Diazinon | Bovine, ovine, caprine | 20 μg/kg | Milk | |
Bovine, porcine, ovine, caprine | 20 μg/kg | Muscle | |||
700 μg/kg | Fat | ||||
20 μg/kg | Liver | ||||
20 μg/kg | Kidney | ||||
[F15Phoxim | Phoxim | Ovine | 50 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
400 μg/kg | Fat | ||||
50 μg/kg | Kidney | ||||
Porcine | 20 μg/kg | Muscle | |||
700 μg/kg | Skin and fat | ||||
20 μg/kg | Liver | ||||
20 μg/kg | Kidney | ||||
[F5Chicken | 25 μg/kg | Muscle | |||
550 μg/kg | Skin + fat | ||||
50 μg/kg | Liver | ||||
30 μg/kg | Kidney | ||||
60 μg/kg | Eggs | ] ] |
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Amitraz | Sum of amitraz and all metabolites containing the 2,4-DMA moiety, expressed as amitraz | Bovine | 200 μg/kg | Fat | |
200 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
10 μg/kg | Milk | ||||
Ovine | 400 μg/kg | Fat | |||
100 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
10 μg/kg | Milk | ||||
Porcine | 400 μg/kg | Skin and fat | |||
200 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
[F36 | Bees (honey) | 200 μg/kg | Honey | ] | |
[F43 | Caprine | 200 μg/kg | Fat | ||
100 μg/kg | Liver | ||||
200 μg/kg | Kidney | ||||
10 μg/kg | Milk | ] |
Textual Amendments
F43 Inserted by Commission Regulation (EC) No 1646/2004 of 20 September 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
a [F13Further provisions in Commission Directive 98/82/EC are to be observed ( OJ L 290, 29.10.1998, p. 25 ).] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F15 [X3Cyhalothrin | Cyhalothrin (sum of isomers) | Bovine | 500 μg/kg | Fat | Further provisions in Council Directive 94/29/EC are to be observed |
50 μg/kg | Kidney | ||||
50 μg/kg | Milk | ||||
Cyfluthrin | Cyfluthrin (sum of isomers) | Bovine | 10 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
10 μg/kg | Liver | ||||
10 μg/kg | Kidney | ||||
20 μg/kg | Milk] ] | ||||
[F44 [F35Deltamethrin | Deltamethrin | All ruminants | 10 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
10 μg/kg | Liver | ||||
10 μg/kg | Kidney | ||||
20 μg/kg | Milk] | ||||
[F11Fin fish | 10 μg/kg | Muscle and skin in natural proportions] ] | |||
[F45Fenvalerate | Fenvalerate (sum of RR, SS, RS and SR isomers) | Bovine | 25 μg/kg | Muscle | |
250 μg/kg | Fat | ||||
25 μg/kg | Liver | ||||
25 μg/kg | Kidney | ||||
40 μg/kg | Milk] | ||||
Flumethrin | Flumethrin (sum of trans-Z isomers) | Bovine | 10 μg/kg | Muscle | |
150 μg/kg | Fat | ||||
20 μg/kg | Liver | ||||
10 μg/kg | Kidney | ||||
30 μg/kg | Milk | ||||
[F46 | Ovine | 10 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption | |
150 μg/kg | Fat | ||||
20 μg/kg | Liver | ||||
10 μg/kg | Kidney | ] | |||
[F13Permethrin | Permethrin (sum of isomers) | Bovine | 50 μg/kg | Muscle | |
500 μg/kg | Fat | ||||
50 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
50 μg/kg | Milk a | ] | |||
[F47Cypermethrin | Cypermethrin (sum of isomers) | Salmonidae | 50 μg/kg | Muscle and skin in natural proportions | ] |
[F35All ruminants | 20 μg/kg | Muscle | |||
200 μg/kg | Fat | ||||
20 μg/kg | Liver | ||||
20 μg/kg | Kidney | ||||
20 μg/kg | Milk a | ] | |||
[F48Alphacypermethrin | Cypermethrin (sum of isomers) | Bovine, ovine | 20 μg/kg | Muscle | |
200 μg/kg | Fat | ||||
20 μg/kg | Liver | ||||
20 μg/kg | Kidney | ||||
20 μg/kg | Milk] a |
Textual Amendments
F44 Inserted by Commission Regulation (EC) No 1815/2001 of 14 September 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F45 Inserted by Commission Regulation (EC) No 1805/2006 of 7 December 2006 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards thiamphenicol, fenvalerate and meloxicam (Text with EEA relevance).
F46 Inserted by Commission Regulation (EC) No 2391/2000 of 27 October 2000 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F47 Inserted by Commission Regulation (EC) No 1029/2003 of 16 June 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F48 Inserted by Commission Regulation (EC) No 2011/2003 of 14 November 2003 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
a [F49Not for use in animals from which milk is produced for human consumption.] ] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F25Diflubenzuron | Diflubenzuron | Salmonidae | 1 000 μg/kg | Muscle and skin in natural proportions | ] |
[F49Fluazuron | Fluazuron | Bovine a | 200 μg/kg | Muscle | |
7 000 μg/kg | Fat | ||||
500 μg/kg | Liver | ||||
500 μg/kg | Kidney] | ||||
Teflubenzuron | Teflubenzuron | Salmonidae | 500 μg/kg | Muscle and skin in natural proportions |
Textual Amendments
F49 Inserted by Commission Regulation (EC) No 1451/2006 of 29 September 2006 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards fluazuron, sodium nitrite and peforelin (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Dicyclanil | Sum of dicyclanil and 2, 4, 6-triamino-pyrimidine-5-carbonitrile | Ovine | 200 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
[F51150 μg/kg] | Fat | ||||
400 μg/kg | Liver | ||||
400 μg/kg | Kidney] |
Textual Amendments
F51 Substituted by Commission Regulation (EC) No 2391/2000 of 27 October 2000 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Textual Amendments
F50 Inserted by Commission Regulation (EC) No 1960/2000 of 15 September 2000 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Cyromazine | Cyromazine | Ovine | 300 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
300 μg/kg | Fat | ||||
300 μg/kg | Liver | ||||
300 μg/kg | Kidney] |
a [F52Not for use in animals from which milk is produced for human consumption.] | |||||
Phramacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Abamectin | Avermectin B1a | Bovine | 10 μg/kg | Fat | |
20 μg/kg | Liver | ||||
[F31 | Ovine | 20 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption | |
50 μg/kg | Fat | ||||
25 μg/kg | Liver | ||||
20 μg/kg | Kidney | ] | |||
[F53Doramectin | Doramectin | All mammalian food producing species a | 40 μg/kg | Muscle | |
150 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
60 μg/kg | Kidney] | ||||
[F54Emamectin | Emamectin B1a | Fin fish | 100 μg/kg | Muscle and skin in natural proportions | ] |
Eprinomectin | Eprinomectin B1a | Bovine | [F5550 μg/kg] | Muscle | |
[F55250 μg/kg] | Fat | ||||
[F551 500 μg/kg] | Liver | ||||
[F55300 μg/kg] | Kidney | ||||
[F5520 μg/kg] | Milk | ||||
Ivermectin | 22, 23-Dihydro-avermectin B1a | Bovine | 40 μg/kg | Fat | |
100 μg/kg | Liver | ||||
Porcine, ovine, equidae | 20 μg/kg | Fat | |||
15 μg/kg | Liver | ||||
Deer, including reindeer | 20 μg/kg | Muscle | |||
100 μg/kg | Fat | ||||
50 μg/kg | Liver | ||||
20 μg/kg | Kidney | ||||
[F56 | All mammalian food-producing species a | 100 μg/kg | Fat | ||
100 μg/kg | Liver | ||||
30 μg/kg | Kidney | ] | |||
Moxidectin | Moxidectin | Bovine, ovine | 50 μg/kg | Muscle | |
500 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
50 μg/kg | Kidney | ||||
[F14 | Bovine | 40 μg/kg | Milk | ] | |
[F41 | Equidae | 50 μg/kg | Muscle | ||
500 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
50 μg/kg | Kidney | ] | |||
[F57 | Ovine | 40 μg/kg | Milk | ] |
Textual Amendments
F52 Inserted by Commission Regulation (EC) No 869/2005 of 8 June 2005 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards ivermectin and carprofen (Text with EEA relevance).
F53 Substituted by Commission Regulation (EC) No 1831/2006 of 13 December 2006 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards Doramectin (Text with EEA relevance).
F54 Substituted by Commission Regulation (EC) No 1490/2003 of 25 August 2003 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F55 Substituted by Commission Regulation (EC) No 1943/1999 of 10 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
F56 Substituted by Commission Regulation (EC) No 869/2005 of 8 June 2005 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards ivermectin and carprofen (Text with EEA relevance).
F57 Inserted by Commission Regulation (EC) No 75/2005 of 18 January 2005 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards moxidectin, linear alkyl benzene sulphonic acids with alkyl chain lengths ranging from C9 to C13, containing less than 2,5 % of chains longer than C13 and Acetylisovaleryltylosin (Text with EEA relevance).
a [F58Not for use in animals from which milk is produced for human consumption. | |||||
b For porcine species this MRL relates to ‘ skin and fat in natural proportions ’ . | |||||
c Not for use in animals from which eggs are produced for human consumption.] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Toltrazuril | Toltrazuril sulfone | Chicken | 100 μg/kg | Muscle | Not for use in animals from which eggs are produced for human consumption |
200 μg/kg | Skin and fat | ||||
600 μg/kg | Liver | ||||
400 μg/kg | Kidney | ||||
Turkey | 100 μg/kg | Muscle | |||
200 μg/kg | Skin and fat | ||||
600 μg/kg | Liver | ||||
400 μg/kg | Kidney | ||||
[F59 | Porcine | 100 μg/kg | Muscle | ||
150 μg/kg | Skin and fat | ||||
500 μg/kg | Liver | ||||
250 μg/kg | Kidney | ] | |||
[F58 | All mammalian food producing species a | 100 μg/kg | Muscle | ||
150 μg/kg | Fat b | ||||
500 μg/kg | Liver | ||||
250 μg/kg | Kidney | ||||
Poultry c | 100 μg/kg | Muscle | |||
200 μg/kg | Skin + fat | ||||
600 μg/kg | Liver | ||||
400 μg/kg | Kidney | ] |
Textual Amendments
F58 Inserted by Commission Regulation (EC) No 205/2006 of 6 February 2006 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards toltrazuril, diethylene glycol monoethyl ether and polyoxyethylene sorbitan monooleate (Text with EEA relevance).
F59 Inserted by Commission Regulation (EC) No 2908/2000 of 29 December 2000 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Halofuginone | Halofuginone | Bovine | 10 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
25 μg/kg | Fat | ||||
30 μg/kg | Liver | ||||
30 μg/kg | Kidney] |
a [F17Not for use in ovine from which milk is produced for human consumption.] ] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Imidocarb | Imidocarb | Bovine | 300 μg/kg | Muscle | |
50 μg/kg | Fat | ||||
2 000 μg/kg | Liver | ||||
1 500 μg/kg | Kidney | ||||
50 μg/kg | Milk | ||||
[F17Ovine a | 300 μg/kg | Muscle | |||
50 μg/kg | Fat | ||||
2 000 μg/kg | Liver | ||||
1 500 μg/kg | Kidney | ] |
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F37Lasalocid | Lasalocid A | Poultry | 20 μg/kg | Muscle | |
100 μg/kg | Skin + fat | ||||
100 μg/kg | Liver | ||||
50 μg/kg | Kidney] ] |
Textual Amendments
F60 Inserted by Commission Regulation (EC) No 712/2005 of 11 May 2005 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards lasalocid and ammonium and sodium salts of bituminosulfonates (Text with EEA relevance).
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Azaperone | Sum of azaperone and azaperol | Porcine | 100 μg/kg | Muscle | |
100 μg/kg | Skin and fat | ||||
100 μg/kg | Liver | ||||
100 μg/kg | Kidney |
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Carazolol | Carazolol | Porcine | 5 μg/kg | Muscle | |
5 μg/kg | Skin and fat | ||||
25 μg/kg | Liver | ||||
25 μg/kg | Kidney | ||||
[F7 | Bovine | 5 μg/kg | Muscle | ||
5 μg/kg | Fat | ||||
15 μg/kg | Liver | ||||
15 μg/kg | Kidney | ||||
1 μg/kg | Milk | ] |
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Clenbuterol hydrochloride | Clenbuterol | Bovine | 0,1 μg/kg | Muscle | |
0,5 μg/kg | Liver | ||||
0,5 μg/kg | Kidney | ||||
0,05 μg/kg | Milk | ||||
Equidae | 0,1 μg/kg | Muscle | |||
0,5 μg/kg | Liver | ||||
0,5 μg/kg | Kidney | ] |
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F16Carprofen | Carprofen | Bovine Not for use in animals from which milk is produced for human consumption | 500 μg/kg | Muscle | |
1 000 μg/kg | Fat | ||||
1 000 μg/kg | Liver | ||||
1 000 μg/kg | Kidney | ||||
Equidae | 500 μg/kg | Muscle | |||
1 000 μg/kg | Fat | ||||
1 000 μg/kg | Liver | ||||
1 000 μg/kg | Kidney | ] | |||
Vedaprofen | Vedaprofen | Equidae | 50 μg/kg | Muscle | |
20 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
1 000 μg/kg | Kidney | ||||
[F52Carprofen | Sum of carprofen and carprofen glucuronide conjugate | Bovine, equidae | 500 μg/kg | Muscle | |
1 000 μg/kg | Fat | ||||
1 000 μg/kg | Liver | ||||
1 000 μg/kg | Kidney] |
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F12Flunixin | Flunixin | Bovine | 20 μg/kg | Muscle | |
30 μg/kg | Fat | ||||
300 μg/kg | Liver | ||||
100 μg/kg | Kidney | ||||
5-Hydroxyflunixin | 40 μg/kg | Milk | |||
Flunixin | Porcine | 50 μg/kg | Muscle | ||
10 μg/kg | Skin and fat | ||||
200 μg/kg | Liver | ||||
30 μg/kg | Kidney | ||||
[F59Equidae | 10 μg/kg | Muscle | |||
20 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
200 μg/kg | Kidney | ] ] | |||
Tolfenamic acid | Tolfenamic acid | Bovine | 50 μg/kg | Muscle | |
400 μg/kg | Liver | ||||
100 μg/kg | Kidney | ||||
50 μg/kg | Milk | ||||
Porcine | 50 μg/kg | Muscle | |||
400 μg/kg | Liver | ||||
100 μg/kg | Kidney |
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Meloxicam | Meloxicam | Equidae | 20 μg/kg | Muscle | |
65 μg/kg | Liver | ||||
65 μg/kg | Kidney | ] |
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F26Meloxicam | Meloxicam | Porcine, equidae, rabbit | 20 μg/kg | Muscle | |
65 μg/kg | Liver | ||||
65 μg/kg | Kidney | ||||
Bovine, caprine | 20 μg/kg | Muscle | |||
65 μg/kg | Liver | ||||
65 μg/kg | Kidney | ||||
15 μg/kg | Milk] ] |
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Metamizole | 4-Methylaminoantipyrin | Bovine | 100 μg/kg | Muscle | |
100 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
100 μg/kg | Kidney | ||||
50 μg/kg | Milk | ||||
Porcine | 100 μg/kg | Muscle | |||
100 μg/kg | Skin and fat | ||||
100 μg/kg | Liver | ||||
100 μg/kg | Kidney | ||||
Equidae | 100 μg/kg | Muscle | |||
100 μg/kg | Fat | ||||
100 μg/kg | Liver | ||||
100 μg/kg | Kidney | ] |
a Not for use in animals from which milk is produced for human consumption.] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Diclofenac | Diclofenac | Bovine a | 5 μg/kg | Muscle | |
1 μg/kg | Fat | ||||
5 μg/kg | Liver | ||||
10 μg/kg | Kidney | ||||
Porcine | 5 μg/kg | Muscle | |||
1 μg/kg | Skin + fat | ||||
5 μg/kg | Liver | ||||
10 μg/kg | Kidney |
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
[F25Betamethasone | Betamethasone | Bovine | 0,75 μg/kg | Muscle | |
2,0 μg/kg | Liver | ||||
0,75 μg/kg | Kidney | ||||
0,3 μg/kg | Milk | ||||
Porcine | 0,75 μg/kg | Muscle | |||
2,0 μg/kg | Liver | ||||
0,75 μg/kg | Kidney | ] | |||
Dexamethasone | Dexamethasone | Bovine | 0,3 μg/kg | Milk | |
Bovine, porcine, equidae | 0,75 μg/kg | Muscle | |||
2 μg/kg | Liver | ||||
0,75 μg/kg | Kidney | ||||
[F43 | Caprine | 0,75 μg/kg | Muscle | ||
2 μg/kg | Liver | ||||
0,75 μg/kg | Kidney | ||||
0,3 μg/kg | Milk] | ||||
[F24Methylprednisolone | Methylprednisolone | Bovine | 10 μg/kg | Muscle | Not for use in animals from which milk is produced for human consumption |
10 μg/kg | Fat | ||||
10 μg/kg | Liver | ||||
10 μg/kg | Kidney] | ||||
[F61Prednisolone | Prednisolone | Bovine | 4 μg/kg | Muscle | |
4 μg/kg | Fat | ||||
10 μg/kg | Liver | ||||
10 μg/kg | Kidney | ||||
6 μg/kg | Milk | ] |
Textual Amendments
F61 Inserted by Commission Regulation (EC) No 2535/2000 of 17 November 2000 amending Annex I of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
a [F63Only for zootechnical use and in accordance with the provisions of Directive 96/22/EC. | |||||
b [F5For therapeutic and zootechnical purposes only.] ] ] ] | |||||
Pharmacologically active substance(s) | Marker residue | Animal species | MRLs | Target tissues | Other provisions |
---|---|---|---|---|---|
Chlormadinone | Chlormadinone | Bovine | 4 μg/kg | Fat | For zootechnical use only |
2 μg/kg | Liver | ||||
2,5 μg/kg | Milk | ||||
Flugestone acetate | Flugetone acetate | Ovine | 1 μg/kg | Milk | For intravaginal use for zootechnical purposes only |
[F21Caprine | 1 μg/kg | Milk | For intra-vaginal use for zootechnical purposes only] | ||
[F64Ovine, caprine | 0,5 μg/kg | Muscle | For therapeutic and zootechnical purposes only | ||
0,5 μg/kg | Fat | ||||
0,5 μg/kg | Liver | ||||
0,5 μg/kg | Kidney] | ||||
[F63Altrenogest a | Altrenogest | Porcine | 1 μg/kg | Skin and fat | |
0,4 μg/kg | Liver | ||||
Equidae | 1 μg/kg | Fat | |||
0,9 μg/kg | Liver] | ||||
[F5Norgestomet b | Norgestomet | Bovine | 0,2 μg/kg | Muscle | |
0,2 μg/kg | Fat | ||||
0,2 μg/kg | Liver | ||||
0,2 μg/kg | Kidney | ||||
0,12 μg/kg | Milk | ] |
Textual Amendments
F63 Inserted by Commission Regulation (EC) No 2232/2004 of 23 December 2004 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards altrenogest, beclomethasone dipropionate, cloprostenol, r-cloprostenol, sorbitan sesquioleate and toltrazuril (Text with EEA relevance).
F64 Inserted by Commission Regulation (EC) No 1911/2005 of 23 November 2005 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards flugestone acetate (Text with EEA relevance).
Textual Amendments
F62 Inserted by Council Regulation (EC) No 2584/2001 of 19 December 2001 amending Annexes I and III of Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
Y Diweddaraf sydd Ar Gael (diwygiedig):Y fersiwn ddiweddaraf sydd ar gael o’r ddeddfwriaeth yn cynnwys newidiadau a wnaed gan ddeddfwriaeth ddilynol ac wedi eu gweithredu gan ein tîm golygyddol. Gellir gweld y newidiadau nad ydym wedi eu gweithredu i’r testun eto yn yr ardal ‘Newidiadau i Ddeddfwriaeth’.
Gwreiddiol (Fel y’i mabwysiadwyd gan yr UE): Mae'r wreiddiol version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Pwynt Penodol mewn Amser: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Rhychwant ddaearyddol: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Dangos Llinell Amser Newidiadau: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Gallwch wneud defnydd o ddogfennau atodol hanfodol a gwybodaeth ar gyfer yr eitem ddeddfwriaeth o’r tab hwn. Yn ddibynnol ar yr eitem ddeddfwriaeth sydd i’w gweld, gallai hyn gynnwys:
Mae’r llinell amser yma yn dangos y fersiynau gwahanol a gymerwyd o EUR-Lex yn ogystal ag unrhyw fersiynau dilynol a grëwyd ar ôl y diwrnod ymadael o ganlyniad i newidiadau a wnaed gan ddeddfwriaeth y Deyrnas Unedig.
Cymerir dyddiadau fersiynau’r UE o ddyddiadau’r dogfennau ar EUR-Lex ac efallai na fyddant yn cyfateb â’r adeg pan ddaeth y newidiadau i rym ar gyfer y ddogfen.
Ar gyfer unrhyw fersiynau a grëwyd ar ôl y diwrnod ymadael o ganlyniad i newidiadau a wnaed gan ddeddfwriaeth y Deyrnas Unedig, bydd y dyddiad yn cyd-fynd â’r dyddiad cynharaf y daeth y newid (e.e. ychwanegiad, diddymiad neu gyfnewidiad) a weithredwyd i rym. Am ragor o wybodaeth gweler ein canllaw i ddeddfwriaeth ddiwygiedig ar Ddeall Deddfwriaeth.
Defnyddiwch y ddewislen hon i agor dogfennau hanfodol sy’n cyd-fynd â’r ddeddfwriaeth a gwybodaeth am yr eitem hon o ddeddfwriaeth. Gan ddibynnu ar yr eitem o ddeddfwriaeth sy’n cael ei gweld gall hyn gynnwys:
liciwch ‘Gweld Mwy’ neu ddewis ‘Rhagor o Adnoddau’ am wybodaeth ychwanegol gan gynnwys